Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
arcticnovartis
Wed, 10/22/2025 – 07:19
Read more about Novartis Cosentyx® meets primary and all secondary endpoints in Ph…
